Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: Cohort and case–control study

Eurosurveillance

Volumn 21, Issue 14, 2016, Pages

  Guevara, Marcela ^a,b,c   Barricarte, A ^a,b,c   Torroba, L ^b,d   Herranz, M ^b,d   Gil Setas, A ^b,d   Gil, F ^e   Bernaola, E ^b,d   Ezpeleta, C ^b,d   Castilla, J ^a,b,c   Chamorro, Judith ^d   Gabari, Mercedes ^d   Artajo, Pilar ^d   Peña, Luz ^d   Clerigué, Nuria ^d   Polo, Isabel ^d   Martín, Carmen ^d   Mazón, Ana ^d   Moreno Galarraga, Laura ^d   Viguria Sánchez, Natividad ^d   Leiva, José ^f   Núnez Córdoba, Jorge M ^f   Ortega, María Teresa ^g   Torres, Montse ^g   García Irure, José Javier ^g   Barrado, Laura ^e   Lameiro, Francisco ^e   Álvarez, Nerea ^h   Cenoz, Manuel García ^a   Irisarri, Fátima ^a   Arriazu, Maite ^a   Casado, Itziar ^a   Martínez Baz, Iván ^a   Zabala, Agurtzane ^a   Castilla, Jesús ^a   more..

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e HOSPITAL GARCÍA ORCOYEN   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

^h Servicio Navarro de Salud   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MALE; PNEUMOCOCCAL INFECTION; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION; CLASSIFICATION; HEALTH SURVEY; INCIDENCE; ISOLATION AND PURIFICATION; MASS IMMUNIZATION; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; SEROTYPING; STATISTICS AND NUMERICAL DATA;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MASS VACCINATION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROGROUP; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84963563078     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.14.30186     Document Type: Article

References (30)

1. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006; 368(9546): 1495-502. DOI: 10. 1016/S0140-6736(06)69637-2 PMID: 17071283
2. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RA, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009; 7(4): CD004977. DOI: 10. 1002/14651858. CD004977. pub2 PMID: 19821336 PMID: 19821336
3. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807): 1962-73. DOI: 10. 1016/S0140-6736(10)62225-8 PMID: 21492929
4. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines. 2011; 10(2): 187-99. DOI: 10. 1586/erv. 10. 163 PMID: 21332268
5. World Health Organization (WHO). Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series 927, fifty-fourth report. Annex 2. Geneva: WHO; 2005. Available from: http: //apps. who. int/ medicinedocs/documents/s16102e/s16102e. pdf
6. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29(49): 9127-31. DOI: 10. 1016/j. vaccine. 2011. 09. 112 PMID: 21983361
7. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014; 14(9): 839-46. DOI: 10. 1016/S1473-3099(14)70822-9 PMID: 25042756
8. Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015; 33(23): 2684-9. DOI: 10. 1016/j. vaccine. 2015. 04. 005 PMID: 25887086
9. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013; 32(1): 133-45. DOI: 10. 1016/j. vaccine. 2013. 05. 005 PMID: 23684824
10. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8): 1066-73. DOI: 10. 1093/ cid/ciu524 PMID: 25034421
11. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3): 301-9. DOI: 10. 1016/S1473-3099(14)71081-3 PMID: 25656600
12. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15(5): 535-43. DOI: 10. 1016/S1473-3099(15)70044-7 PMID: 25801458
13. Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997; 146(10): 789-803. DOI: 10. 1093/ oxfordjournals. aje. a009196 PMID: 9384199
14. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in postlicensure studies. Vaccine. 2013; 31(48): 5634-42. DOI: 10. 1016/j. vaccine. 2013. 07. 006 PMID: 23856332
15. Instituto de Salud Pública de Navarra [Public Health Institute of Navarra]. Instrucciones sobre la vacunación de adultos y en situaciones clínicas especiales [Instructions on vaccination of adults and patients in special clinical situations]. Boletín Informativo. 2013; 72: 1-3. Spanish. [Accessed July 2015]. Available from: http: //www. navarra. es/NR/rdonlyres/ AECCD760-AB2A-4841-818A-FA53478FD6DC/255921/BOL72INT. pdf
16. Advisory Committee on Vaccines of the Spanish Association of Pediatrics, Moreno-Pérez D, Alvarez García FJ, Aristegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM, et al.. Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations. An Pediatr (Barc). 2012; 76(1): 43. e1-23. DOI: 10. 1016/j. anpedi. 2011. 10. 008 PMID: 22177960
17. Working Group for Surveillance of the Pneumococcal Disease in Navarre, Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, et al.. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine. 2014; 32(22): 2553-62. DOI: 10. 1016/j. vaccine. 2014. 03. 054 PMID: 24674661
18. Oxford Invasive Pneumococcal Surveillance Group, Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al.. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis. 2014; 210(7): 1001-11. DOI: 10. 1093/infdis/jiu213 PMID: 24719477
19. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013; 31(52): 6232-8. DOI: 10. 1016/j. vaccine. 2013. 10. 032 PMID: 24176490
20. Portuguese Group for the Study of Streptococcal Infections, Aguiar SI, Brito MJ, Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J, et al.. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012. Euro Surveill. 2014; 19(12): 20750. DOI: 10. 2807/1560-7917. ES2014. 19. 12. 20750 PMID: 24698140
21. Microbiologists of Epibac, Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al.. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015; 33(2): 359-66. DOI: 10. 1016/j. vaccine. 2014. 11. 011 PMID: 25448105
22. Instituto Nacional de Estadística, España [National Statistics Institute, Spain]. INEbase. Estadística del Padrón Continuo. Datos nacionales, por CCAA y por provincias. [Continuous Register Statistics. National level data, by autonomous community and province] [Accessed July 2015]. Available from: http: //www. ine. es/jaxi/menu. do?type=pcaxis&path=/t20/ e245/&file=inebase.
23. Aguilar I, Reyes M, Martínez-Baz I, Guevara M, Albeniz E, Belza M, et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill. 2012; 17(17): 20154. PMID: 22551499
24. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007; 297(16): 1784-92. DOI: 10. 1001/jama. 297. 16. 1784 PMID: 17456820
25. Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009; 15(11): 1013-9. DOI: 10. 1111/j. 1469-0691. 2009. 02904. x PMID: 19673968
26. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA. 2010; 304(10): 1099-106. DOI: 10. 1001/ jama. 2010. 1290 PMID: 20823436
27. Serotype Replacement Study Group, Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al.. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10(9): e1001517. DOI: 10. 1371/journal. pmed. 1001517 PMID: 24086113
28. van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015; 15(1): 207. DOI: 10. 1186/s12879-015-0941-9 PMID: 25940580
29. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011; 10(7): 951-80. DOI: 10. 1586/erv. 11. 76 PMID: 21806394
30. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J. 2014; 33(5): 504-10. DOI: 10. 1097/ INF. 0000000000000279 PMID: 24670957